Abstract
Almonertinib is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with demonstrated activity against EGFR sensitizing mutations and EGFR T790M mutation. Despite the success of almonertinib, acquired resistance inevitably occurs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have